Autres langues Regeneron Pharmaceuticals, Inc.

Actions

REGN

US75886F1075

Produits pharmaceutiques

Temps réel estimé Cboe BZX 21:54:26 07/10/2026			Varia. 5j.	Varia. 1 janv.
741,47 ^USD	+0,37%		-2,19%	-3,91%

15:03	Regeneron Pharmaceuticals, Inc. : Morgan Stanley persiste à l'achat	ZM
06:52	Selon Berenberg, l’élargissement de la collaboration entre Sanofi et Regeneron en immunologie prolonge leur « domination » dans les maladies atopiques	MT

Autres langues

06:52	Berenberg Says Sanofi, Regeneron's Expanded Immunology Collaboration Extends 'Dominance' in Atopic Diseases
06:15	ANALYSEN DES TAGES von Dow Jones Newswires (06.10.2026)
06/10	Regeneron Pharmaceuticals, Inc. Announces Presentation of New Clinical Research At European Society for Medical Oncology Congress 2026
06/10	ANALYSEN DES TAGES von Dow Jones Newswires (06.10.2026)
06/10	HINTERGRUND/Adipositas-Medikamente stoßen in neue Dimensionen vor
06/10	Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026
02/10	Major drugmakers turn to China for licensing deals
02/10	MORNING BRIEFING - Deutschland/Europa
01/10	Healthcare Stocks Among Top Losers -- Healthcare Roundup
01/10	Aktien Europa Schluss: Ölpreise und Anleiherenditen belasten die Märkte
01/10	Regeneron Says Trevogrumab Preserves Muscle During GLP-1-Induced Weight Loss
01/10	Regeneron Says Ongoing Phase 1/2 Ovarian Cancer Trial With Ubamatamab Showed High Rate of Durable Responses
01/10	Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)
01/10	Regeneron Pharmaceuticals, Inc. Announces the First Results for the Investigational Ubamatamab in Patients with Low-Grade Serous Ovarian Cancer
01/10	Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss
01/10	Regeneron Pharmaceuticals, Inc. Announces New Results From Phase 2 COURAGE Trial Evaluating Trevogrumab
01/10	Sanofi, Regeneron to Expand Alliance in Up to $8 Billion Deal -- Update
01/10	Analyst recommendations: Alphabet, Amazon, Micron, Tesla, Eli Lilly…
01/10	Tech setzt darauf, dass die Wirtschaft hohe Zinsen verkraftet
01/10	Exchange-Traded Funds, Equity Futures up Pre-Bell Thursday as Traders Assess Micron's Fiscal Q4 Results
01/10	Sanofi Expands Regeneron Partnership with Four New Antibodies for Up to $8 Billion
01/10	Sanofi, Regeneron Expand Immunology Partnership in $1 Billion Deal
01/10	Sanofi zahlt für neue Antikörper bis zu acht Milliarden Dollar an Regeneron
01/10	Regeneron Pharmaceuticals, Inc. And Sanofi Expand Global Alliance With Multiple Next-Generation, Long-Acting Immunology Antibodies
01/10	Sanofi : accordo da 1 mld $ con Regeneron per sviluppo nuovi anticorpi